September 5, 2025New England Journal of Medicine
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Authors
Discussion
Loading...
Member takes
Implication
Phase 3 trial demonstrates olezarsen reduces triglyceride levels significantly in moderate hypertriglyceridemia patients, suggesting promising therapeutic potential.
Key Points
- Olezarsen successfully reduced triglyceride levels by 58.4% in the 50-mg group and 60.6% in the 80-mg group compared to placebo.
- Among 1349 patients with moderate hypertriglyceridemia, the drug showed a significant placebo-adjusted change in triglyceride levels at 6 months.
- In this randomized, double-blind, placebo-controlled trial, patients received either olezarsen or a matching placebo to assess efficacy.
- Results highlight the potential of olezarsen as an effective treatment for managing triglyceride levels, although adverse events remained similar across groups.
Cite This Study
Bergmark et al. (2025) studied this question.